Akoya Biosciences acquires PerkinElmer's multispectral imaging portfolio
The Phenoptics multispectral imaging portfolio supports large-scale translational studies.
Immunofluorescence tissue analysis specialist Akoya Biosciences (Menlo Park, CA) has acquired the Phenoptics multispectral imaging portfolio for quantitative pathology from PerkinElmer (Waltham, MA). Akoya was founded in 2015 to commercialize the CODEX multiparameter tissue analysis technology developed in the lab of Dr. Garry Nolan at Stanford University (Stanford, CA). The acquisition enables Akoya to provide quantitative tissue biomarker evaluation, from discovery through translational and clinical research.
High-parameter analysis of biological tissue samples provides critical spatial context in studies of autoimmune disease, immune-oncology, and many other research areas. The Phenoptics portfolio, with its Mantra, Vectra, and Vectra Polaris systems, provides the throughput and standardization required to support large-scale translational studies. Its multispectral imaging instruments, reagents, software, and research services have been adopted by hundreds of labs globally. CODEX enables biomarker discovery with detection of up to 50 markers on a single tissue section with reagents and instrumentation that integrate with existing microscopes. CODEX includes optimized assay reagents combined with validated antibodies labeled with proprietary CODEX Barcodes to enable a simple, automated workflow.
Concurrent with the acquisition, PerkinElmer’s Phenoptics team's management, R&D, sales, and support staff have joined Akoya. Akoya will continue to operate this team out of Waltham and maintain headquarters in Menlo Park. Brian McKelligon will remain as CEO of Akoya and Terry Lo, general manager of the Phenoptics team at PerkinElmer, will join Akoya as president.
For more information, please visit www.akoyabio.com.